Published in Gastroenterology on April 16, 2009
FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res (2009) 1.96
Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target. Int J Biol Sci (2011) 1.70
Breaking patterns of environmentally influenced disease for health risk reduction: immune perspectives. Environ Health Perspect (2010) 1.58
Adiponectin, a key adipokine in obesity related liver diseases. World J Gastroenterol (2011) 1.41
Hepatic macrophages but not dendritic cells contribute to liver fibrosis by promoting the survival of activated hepatic stellate cells in mice. Hepatology (2013) 1.40
Leptin promotes the myofibroblastic phenotype in hepatic stellate cells by activating the hedgehog pathway. J Biol Chem (2010) 1.33
HIV and HCV cooperatively promote hepatic fibrogenesis via induction of reactive oxygen species and NFkappaB. J Biol Chem (2010) 1.24
Obesity, diabetes mellitus, and liver fibrosis. Am J Physiol Gastrointest Liver Physiol (2011) 1.24
Apoptosis and cytokines in non-alcoholic steatohepatitis. Clin Liver Dis (2009) 1.21
Immune mechanisms of Concanavalin A model of autoimmune hepatitis. World J Gastroenterol (2012) 1.18
Hepatic stellate cells: partners in crime for liver metastases? Hepatology (2011) 1.17
Mononuclear cells in liver fibrosis. Semin Immunopathol (2009) 1.15
Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals. Endocr Rev (2013) 1.10
Cell death and fibrogenesis. Semin Liver Dis (2010) 1.09
Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol (2014) 1.04
Leptin is key to peroxynitrite-mediated oxidative stress and Kupffer cell activation in experimental non-alcoholic steatohepatitis. J Hepatol (2012) 1.04
Cytokines and STATs in Liver Fibrosis. Front Physiol (2012) 1.02
Molecular mechanisms of liver fibrosis in HIV/HCV coinfection. Int J Mol Sci (2014) 1.01
Novel insights into the function and dynamics of extracellular matrix in liver fibrosis. Am J Physiol Gastrointest Liver Physiol (2015) 0.97
Pathophysiology of NASH: perspectives for a targeted treatment. Curr Pharm Des (2013) 0.95
Environmental toxin-linked nonalcoholic steatohepatitis and hepatic metabolic reprogramming in obese mice. Toxicol Sci (2013) 0.94
TGF-β/SMAD Pathway and Its Regulation in Hepatic Fibrosis. J Histochem Cytochem (2016) 0.93
Micro-RNA 21 inhibition of SMAD7 enhances fibrogenesis via leptin-mediated NADPH oxidase in experimental and human nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol (2014) 0.93
Chronic hepatitis C and liver fibrosis. World J Gastroenterol (2014) 0.92
Proinflammatory adipokine leptin mediates disinfection byproduct bromodichloromethane-induced early steatohepatitic injury in obesity. Toxicol Appl Pharmacol (2013) 0.90
CYP2E1-dependent and leptin-mediated hepatic CD57 expression on CD8+ T cells aid progression of environment-linked nonalcoholic steatohepatitis. Toxicol Appl Pharmacol (2013) 0.86
Clinical significance of connective tissue growth factor in hepatitis B virus-induced hepatic fibrosis. World J Gastroenterol (2012) 0.85
Leptin ameliorates insulin resistance and hepatic steatosis in Agpat2-/- lipodystrophic mice independent of hepatocyte leptin receptors. J Lipid Res (2013) 0.83
Adiponectin upregulates hepatocyte CMKLR1 which is reduced in human fatty liver. Mol Cell Endocrinol (2011) 0.83
Sparstolonin B attenuates early liver inflammation in experimental NASH by modulating TLR4 trafficking in lipid rafts via NADPH oxidase activation. Am J Physiol Gastrointest Liver Physiol (2015) 0.81
Two clinical phenotypes in polycythemia vera. N Engl J Med (2014) 0.80
Resistin mediates the hepatic stellate cell phenotype. World J Gastroenterol (2013) 0.80
Contribution and Mobilization of Mesenchymal Stem Cells in a mouse model of carbon tetrachloride-induced liver fibrosis. Sci Rep (2015) 0.80
Liver steatosis in hepatitis C patients. World J Hepatol (2015) 0.79
Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition. Proc Natl Acad Sci U S A (2015) 0.79
Adipose tissue fibrosis. World J Diabetes (2015) 0.79
Galanin receptor 2 mediates antifibrogenic effects of galanin on hepatic stellate cells. Exp Ther Med (2016) 0.78
Liver inflammation and fibrosis. J Clin Invest (2017) 0.77
Upregulation of miR21 and repression of Grhl3 by leptin mediates sinusoidal endothelial injury in experimental nonalcoholic steatohepatitis. PLoS One (2015) 0.77
Adiponectin reduces hepatic stellate cell migration by promoting tissue inhibitor of metalloproteinase-1 (TIMP-1) secretion. J Biol Chem (2015) 0.77
Expression of alpha smooth muscle actin in living donor liver transplant recipients. World J Gastroenterol (2014) 0.76
Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step. Front Pharmacol (2016) 0.76
Demonstration of intrahepatic accumulated microbubble on ultrasound represents the grade of hepatic fibrosis. Eur Radiol (2011) 0.76
STAT3 Inhibition Suppresses Hepatic Stellate Cell Fibrogenesis: HJC0123, a Potential Therapeutic Agent for Liver Fibrosis. RSC Adv (2016) 0.75
High Dietary Fructose: Direct or Indirect Dangerous Factors Disturbing Tissue and Organ Functions. Nutrients (2017) 0.75
Adipokines, cytokines and body fat stores in hepatitis C virus liver steatosis. World J Hepatol (2016) 0.75
The influence of astragalus polysaccharide and β-elemene on LX-2 cell growth, apoptosis and activation. BMC Gastroenterol (2014) 0.75
How Useful Are Monogenic Rodent Models for the Study of Human Non-Alcoholic Fatty Liver Disease? Front Endocrinol (Lausanne) (2016) 0.75
Expression of connective tissue growth factor in the livers of non-viral hepatocellular carcinoma patients with metabolic risk factors. J Gastroenterol (2016) 0.75
Liver fibrosis. J Clin Invest (2005) 17.27
Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med (1996) 16.98
Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology (2002) 2.97
Intracellular signalling pathways activated by leptin. Biochem J (2006) 2.93
Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium. Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. J Clin Invest (1989) 2.46
High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. Hepatology (2001) 2.41
Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver. Hepatology (2002) 2.34
In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. Proc Natl Acad Sci U S A (1999) 2.17
Leptin in hepatic fibrosis: evidence for increased collagen production in stellate cells and lean littermates of ob/ob mice. Hepatology (2002) 2.10
Connective tissue growth factor (CCN2) induces adhesion of rat activated hepatic stellate cells by binding of its C-terminal domain to integrin alpha(v)beta(3) and heparan sulfate proteoglycan. J Biol Chem (2003) 1.98
Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology (1999) 1.94
Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol (2002) 1.86
Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol (2006) 1.84
Loss of SOCS3 in T helper cells resulted in reduced immune responses and hyperproduction of interleukin 10 and transforming growth factor-beta 1. J Exp Med (2006) 1.84
Transforming growth factor beta and the liver. Hepatology (2001) 1.83
IL-17 stimulates MMP-1 expression in primary human cardiac fibroblasts via p38 MAPK- and ERK1/2-dependent C/EBP-beta , NF-kappaB, and AP-1 activation. Am J Physiol Heart Circ Physiol (2007) 1.82
Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. Hepatology (2005) 1.81
Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C. Am J Gastroenterol (2003) 1.75
Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-beta1 production. Oncogene (2006) 1.73
Stimulation of hepatic lipocyte collagen production by Kupffer cell-derived transforming growth factor beta: implication for a pathogenetic role in alcoholic liver fibrogenesis. Hepatology (1990) 1.68
Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology (2002) 1.66
Peroxisome proliferator-activated receptor gamma inhibits transforming growth factor beta-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3. J Biol Chem (2001) 1.52
Oxidative-stress and IL-6 mediate the fibrogenic effects of [corrected] Kupffer cells on stellate cells. Hepatology (2006) 1.50
The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol (2005) 1.49
Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals. Hepatology (2001) 1.46
NF-kappaB and activator protein 1 response elements and the role of histone modifications in IL-1beta-induced TGF-beta1 gene transcription. J Immunol (2006) 1.46
Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen. J Biol Chem (2003) 1.42
Characterization of cell-associated and soluble forms of connective tissue growth factor (CTGF) produced by fibroblast cells in vitro. Growth Factors (1998) 1.32
Transdifferentiation of rat hepatic stellate cells results in leptin expression. Biochem Biophys Res Commun (1998) 1.28
Leptin stimulates tissue inhibitor of metalloproteinase-1 in human hepatic stellate cells: respective roles of the JAK/STAT and JAK-mediated H2O2-dependant MAPK pathways. J Biol Chem (2003) 1.27
Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis. J Hepatol (2000) 1.16
Hepatic ischemic preconditioning in mice is associated with activation of NF-kappaB, p38 kinase, and cell cycle entry. Hepatology (2002) 1.05
Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor. J Biol Chem (2000) 1.01
Leptin enhances the effect of transforming growth factor beta in increasing type I collagen formation. Biochem Biophys Res Commun (2002) 0.96
Phosphoinositide 3-kinase regulation of T cell receptor-mediated interleukin-2 gene expression in normal T cells. J Biol Chem (1998) 0.94
Cross-talk between 1,25-dihydroxyvitamin D3 and transforming growth factor-beta signaling requires binding of VDR and Smad3 proteins to their cognate DNA recognition elements. J Biol Chem (2001) 0.90
Leptin receptor-deficient Zucker (fa/fa) rat retards the development of pig serum-induced liver fibrosis with Kupffer cell dysfunction. Life Sci (2003) 0.89
Sensitization of hepatic lipocytes by high-fat diet to stimulatory effects of Kupffer cell-derived factors: implication in alcoholic liver fibrogenesis. Hepatology (1990) 0.86
Leptin induces TGF-beta synthesis through functional leptin receptor expressed by human peritoneal mesothelial cell. Kidney Int (2006) 0.86
The central role of sinusoidal endothelial cells in hepatic hypoxia-reoxygenation injury in the rat. Hepatology (1996) 0.86
Leptin facilitates proliferation of hepatic stellate cells through up-regulation of platelet-derived growth factor receptor. Biochem Biophys Res Commun (2004) 0.86
Chronic metabolic acidosis alters osteoblast differentiation from human mesenchymal stem cells. Kidney Int (2006) 0.82
The role of hydrogen peroxide produced by polychlorinated biphenyls in PMR1-deficient yeast cells. J Biochem (2003) 0.81
Serum leptin in patients with alcoholic liver disease. Alcohol Clin Exp Res (2006) 0.80
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet (2009) 13.03
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology (2007) 6.68
NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology (2002) 4.44
Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology (2003) 4.10
Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology (2004) 3.93
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem (2006) 3.24
The effects of female sex, viral genotype, and IL28B genotype on spontaneous clearance of acute hepatitis C virus infection. Hepatology (2013) 3.14
Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem (2005) 2.99
Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. Eur Heart J (2006) 2.93
The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology (2011) 2.86
Visceral fat: a key mediator of steatohepatitis in metabolic liver disease. Hepatology (2008) 2.70
Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss. Hepatology (2009) 2.66
Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection. Hepatology (2010) 2.56
Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology (2002) 2.51
Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology (2012) 2.42
Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology (2003) 2.40
Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol (2008) 2.39
Insulin resistance and liver injury in hepatitis C is not associated with virus-specific changes in adipocytokines. Hepatology (2007) 2.36
Animal models of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol (2010) 2.32
Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection. J Hepatol (2012) 2.31
Suppression of RNA interference by adenovirus virus-associated RNA. J Virol (2005) 2.29
Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology (2003) 2.28
Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology (2006) 2.26
Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol (2011) 2.24
Early detection of steatohepatitis in fatty rat liver by using MR elastography. Radiology (2009) 2.12
Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? Hepatology (2011) 2.05
Noninvasive assessment of hepatic lipid composition: Advancing understanding and management of fatty liver disorders. Hepatology (2008) 2.03
Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology (2009) 2.02
Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology (2004) 1.98
Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. Hepatology (2009) 1.91
Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris. J Am Coll Cardiol (2011) 1.88
Identification of bacteria and bacteria-associated chemical cues that mediate oviposition site preferences by Aedes aegypti. Proc Natl Acad Sci U S A (2008) 1.88
Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology (2013) 1.88
The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis (2007) 1.87
The status of glycemic control: A cross-sectional study of outpatients with type 2 diabetes mellitus across primary, secondary, and tertiary hospitals in the Jiangsu province of China. Clin Ther (2010) 1.83
Role of naturally occurring CD4+ CD25+ regulatory T cells in experimental atherosclerosis. Arterioscler Thromb Vasc Biol (2007) 1.79
Plasma interferon-gamma-inducible protein-10 (IP-10) levels during acute hepatitis C virus infection. Hepatology (2013) 1.77
Soluble CD163, a macrophage activation marker, is independently associated with fibrosis in patients with chronic viral hepatitis B and C. Hepatology (2014) 1.73
Treatment of fluorouracil-refractory patients with liver metastases from colorectal cancer by using yttrium-90 resin microspheres plus concomitant systemic irinotecan chemotherapy. J Clin Oncol (2009) 1.70
Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur J Immunol (2008) 1.69
NF-kappaB activation, rather than TNF, mediates hepatic inflammation in a murine dietary model of steatohepatitis. Gastroenterology (2005) 1.67
Subcutaneous emphysema in cavitary pulmonary tuberculosis without pneumothorax or pneumomediastinum. Lung India (2012) 1.67
Lipid peroxidation, stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis. J Hepatol (2003) 1.66
Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology (2002) 1.66
Four-color DNA sequencing with 3'-O-modified nucleotide reversible terminators and chemically cleavable fluorescent dideoxynucleotides. Proc Natl Acad Sci U S A (2008) 1.64
Effect of a lifestyle intervention in patients with abnormal liver enzymes and metabolic risk factors. J Gastroenterol Hepatol (2008) 1.64
Predictive value of high sensitivity CRP in patients with diastolic heart failure. Int J Cardiol (2007) 1.63
Targeted disruption of Smad4 in cardiomyocytes results in cardiac hypertrophy and heart failure. Circ Res (2005) 1.62
Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening. J Hepatol (2009) 1.61
Hepatic fat loss in advanced nonalcoholic steatohepatitis: are alterations in serum adiponectin the cause? Hepatology (2013) 1.57
Predictive factors of type 2 diabetes mellitus remission following bariatric surgery: a meta-analysis. Obes Surg (2015) 1.55
Erythropoietin improves myocardial performance in doxorubicin-induced cardiomyopathy. Eur Heart J (2006) 1.52
Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol (2012) 1.52
The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study. J Am Coll Cardiol (2011) 1.51
Mass screening for prostate cancer: a comparative study in Natori, Japan and Changchun, China. Urology (2003) 1.47
Islet-1 gene delivery improves myocardial performance after experimental infarction. Atherosclerosis (2012) 1.43
Preventing primary liver cancer: how well are we faring towards a national hepatitis B strategy? Med J Aust (2008) 1.42
Diethyl 3,3'-(phenyl-methyl-ene)bis-(1H-indole-2-carboxyl-ate). Acta Crystallogr Sect E Struct Rep Online (2012) 1.42
SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. PLoS Genet (2011) 1.41
Renin-angiotensin system blockers are associated with reduced mortality and heart failure hospitalization in patients paced for complete atrioventricular block. Heart Rhythm (2011) 1.41
Autoantibodies to oxidized low-density lipoprotein in patients with aortic regurgitation: association with aortic diameter size. Cardiology (2014) 1.41
An improved elastase-based method to create a saccular aneurysm rabbit model. Br J Neurosurg (2013) 1.40
Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res (2009) 1.38
IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: a cross-sectional study. PLoS Med (2011) 1.36
Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats. J Hepatol (2003) 1.35
Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs. Semin Liver Dis (2002) 1.32
MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4. J Allergy Clin Immunol (2010) 1.32
Identification of human intestinal alkaline sphingomyelinase as a novel ecto-enzyme related to the nucleotide phosphodiesterase family. J Biol Chem (2003) 1.28
Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells. Anticancer Res (2006) 1.25
COX-2 induction in mice with experimental nutritional steatohepatitis: Role as pro-inflammatory mediator. Hepatology (2006) 1.25
Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock? J Gastroenterol Hepatol (2004) 1.24
Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology (2004) 1.24
HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity. Hepatology (2002) 1.23
Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol (2007) 1.23
Influence of liver cancer on lipid and lipoprotein metabolism. Lipids Health Dis (2006) 1.23
Fitness versus fatness: moving beyond weight loss in nonalcoholic fatty liver disease. Hepatology (2010) 1.22
Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection. J Gastroenterol Hepatol (2002) 1.21
Thrombocytopenia due to rifampicin. Lung India (2012) 1.21
Pathogenesis of NASH: animal models. Clin Liver Dis (2007) 1.20
Signature of circulating microRNAs as potential biomarkers in vulnerable coronary artery disease. PLoS One (2013) 1.19
Hepatic viscoelastic parameters measured with MR elastography: correlations with quantitative analysis of liver fibrosis in the rat. J Magn Reson Imaging (2007) 1.19
Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med (2011) 1.19
IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. J Gastroenterol (2010) 1.18
Dimethyl 3,3'-(phenyl-methyl-ene)bis-(1H-indole-2-carboxyl-ate). Acta Crystallogr Sect E Struct Rep Online (2013) 1.18
Gender differences in healthy ranges for serum alanine aminotransferase levels in adolescence. PLoS One (2011) 1.17
The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol (2005) 1.17
Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol (Oxf) (2002) 1.16
High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol (2013) 1.16
Connective tissue growth factor gene expression alters tumor progression in esophageal cancer. World J Surg (2002) 1.15
Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology (2008) 1.15
Mining protein sequences for motifs. J Comput Biol (2002) 1.15
Assessment of diffusion-weighted MR imaging in liver fibrosis. J Magn Reson Imaging (2007) 1.14
Post-percutaneous nephrolithotomy septic shock and severe hemorrhage: a study of risk factors. Urol Int (2012) 1.14
Soft modes and elasticity of nearly isostatic lattices: randomness and dissipation. Phys Rev Lett (2010) 1.14
Elevated endothelin-1 levels impair nitric oxide homeostasis through a PKC-dependent pathway. Circulation (2006) 1.13
Specific tissue expression and cellular localization of human apolipoprotein M as determined by in situ hybridization. Acta Histochem (2003) 1.13
Immunochemical staining of MT2-MMP correlates positively to angiogenesis of human esophageal cancer. Anticancer Res (2010) 1.12